Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

81.91USD
12:18pm EDT
Change (% chg)

$-0.31 (-0.38%)
Prev Close
$82.22
Open
$82.35
Day's High
$82.58
Day's Low
$81.67
Volume
323,453
Avg. Vol
1,522,898
52-wk High
$82.85
52-wk Low
$60.32

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  ABT.N Industry Sector
P/E (TTM): 84.45 32.13 32.55
EPS (TTM): 0.65 -- --
ROI: 2.24 13.70 13.82
ROE: 4.07 16.39 15.24

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Jun 10 2019

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Jun 10 2019

Abbott Labs quarterly beat overshadowed by unchanged forecast

Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Apr 17 2019

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Apr 17 2019

Abbott Lab's first-quarter sales beat expectations

April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

Apr 17 2019

U.S. joins case against Abbott's Alere over diabetic tests

The U.S. Justice Department on Tuesday said it has joined a whistleblower lawsuit alleging Abbott Laboratories' Alere Inc unit defrauded Medicare into paying for unnecessary testing supplies for diabetic patients.

Feb 19 2019

Abbott's Alere to resolve securities fraud case for $20 million

Alere Inc, now a unit of Abbott Laboratories Inc, has agreed to pay $20 million to resolve claims it made false and misleading statements to investors in the lead up to the announcement of a deal to sell the diagnostic testing company to Abbott.

Feb 04 2019

Abbott escapes lawsuit over recalled St. Jude defibrillators

Jan 25 - Abbott Laboratories has escaped a proposed class action lawsuit alleging its subsidiary St. Jude Medical concealed a potentially deadly battery defect in some of its cardiac defibrillators for years before finally recalling them in 2016.

Jan 25 2019

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Jan 23 2019

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Jan 23 2019

Earnings vs. Estimates